[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.209.213. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1983

Corneal and Conjunctival Effects of Monobenzone in Patients With Vitiligo

Author Affiliations

From the Department of Ophthalmology, Harvard Medical School (Drs Hedges and Kenyon); the Cornea Service, Massachusetts Eye and Ear Infirmary (Drs Hedges and Kenyon); the Department of Cornea Research, Eye Research Institute of Retina Foundation (Dr Kenyon and Ms Hanninen); and the Department of Dermatology, Massachusetts General Hospital (Dr Mosher), Boston.

Arch Ophthalmol. 1983;101(1):64-68. doi:10.1001/archopht.1983.01040010066010
Abstract

• Monobenzone (the monobenzyl ether of hydroquinone [Benoquin]) is used topically by patients with extensive vitiligo to depigment their remaining normally pigmented skin. A patient who had been applying the drug for one year had an anterior linear deposition of pigment in both corneas. Of 15 additional patients with vitiligo, 11 of whom were using monobenzone, acquired conjunctival melanosis in two patients and pingueculae in three may have been related to monobenzone use. Light and electron microscopy of one corneal epithelial scraping and 12 conjunctival biopsy specimens revealed pleomorphic, single-membrane-limited intracytoplasmic inclusions within the corneal epithelium and within the epithelium, fibrocytes, histiocytes, and vascular endothelium of the conjunctiva. The ultrastructural aspects of these inclusions suggested that they are residual bodies containing lipid and lipofuscin.

References
1.
Denton CR, Lerner AB, Fitzpatrick TB:  Inhibition of melanin formation by chemical agents . J Invest Dermatol 1952;18:119-135.
2.
Lerner AB, Fitzpatrick TB:  Treatment of melanin hyperpigmentation . JAMA 1953;152:577-582.Article
3.
Mosher DB, Parrish JA, Fitzpatrick TB:  Monobenzylether of hydroquinone . Br J Dermatol 1977;97:669-679.Article
4.
Albert DM, Nordlund JJ, Lerner AB:  Ocular abnormalities occurring with vitiligo . Ophthalmology 1979;86:1145-1158.Article
5.
Oliver EA, Schwartz L, Warren LH:  Occupational leukoderma . Arch Dermatol 1940;42:993-1014.Article
6.
Dorsey CS:  Dermatitic and pigmentary reactions to monobenzylether of hydroquinone: Report of two cases . Arch Dermatol 1960;81:245-248.Article
7.
MacKinlay JG:  Intense pigmentation of cornea and conjunctiva . Trans Ophthalmol Soc UK 1886;6:144-152.
8.
Anderson B, Oglesby F:  Corneal changes from quinone-hydroquinone exposure . Arch Ophthalmol 1958;59:495-501.Article
9.
Miller SJH:  Ocular ochronosis . Trans Ophthalmol Soc UK 1954;74:349-366.
10.
Velhagen K:  Chinonverfärbung der Lidspaltenzone als Gewerbekrankheit in der Hydro-chinonfabrikation . Klin Monatsbl Augenheilkd 1931;86:739-752.
11.
Straub MW:  Altérations de l'oeil humain par l'hydroquinone . Bull Soc Fr Ophtalmol 1959;72:231-235.
12.
Krahnstöver M:  Schwere Spätschädigung eines Auges durch Hydrochinon . Klin Monatsbl Augenheilkd 1955;126:340-341.
13.
Grant WM: Toxicology of the Eye , ed 2. Springfield, Ill, Charles C Thomas Publisher, 1974, pp 564-567, 878-879.
14.
Anderson B:  Corneal and conjunctival pigmentation among workers engaged in manufacture of hydroquinone . Arch Ophthalmol 1947;38:812-826.Article
15.
Cogan DG, Grant WM:  Corneal and conjunctival pigmentation among workers in hydroquinone . Arch Ophthalmol 1947;38:847-852.Article
16.
Ferraris de Gaspare RF:  Ricerche sperimentali sulla cheratocongiuntivite da idrochinone . Boll Ocul 1949;28:361-367.
17.
Francois J:  Cornea verticillata . Bull Soc Belge Ophtalmol 1968;150:656-670.
18.
Pülhorn G, Thiel HJ:  Das ultrastrukturelle Bild der Chloroquinkeratopathie . Albrect Von Graefes Arch Klin Exp Ophthalmol 1976;201:89-99.Article
19.
Toussaint D, Pohl S:  Aspect histologique et ultrastructure des dépots cornéens dus au chlorhydrate d'amidarone . Bull Soc Belge Ophtalmol 1969;153:676-686.
20.
Libert J: Diagnostic des malades lysosomales de stockage par l'étude de la biopsie conjonctivale en microscopie éléctronique, thésis. Brussels, 1979.
21.
D'Amico DJ, Kenyon KR, Ruskin JN:  Amiodarone keratopathy: Drug-induced lipid storage disease . Arch Ophthalmol 1981;99:257-261.Article
22.
Snell RS:  Monobenzylether of hydroquinone . Arch Dermatol 1964;90:63-70.Article
23.
Frenk E:  Dépigmentation par agents chimiques . Bull Soc Fr Dermatol Syphiligr 1971;78:153-156.
24.
Lerner AB, Fitzpatrick TB, Calkins E, et al:  Mammalian tyrosinase: Preparation and properties . J Biol Chem 1949;178:185-195.
25.
Osler W:  Ochronosis: The pigmentation of cartilages, sclerotics, and skin in alkaptonuria . Lancet 1904;1:10.Article
26.
Daicker B, Riede UN:  Histologische und ultrastrukturelle Befunde bei alkaptonurischer Ochronosis oculi . Ophthalmologica 1974;169:377-388.Article
27.
Kampik A, Sani JN, Green WR:  Ocular ochronosis . Arch Ophthalmol 1980;98:1441-1447.Article
×